(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical ...

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”, or the “Company”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for ...

McLoughlin will oversee all operations across manufacturing, engineering, OPEX, supply chain, quality control (QC), and ...

Sameer Singh brings with him a stellar track record of leadership across global and regional roles in the media, advertising, ...

The global genital herpes treatment market is expected to grow at a CAGR of 5.2% from 2023 to 2033. Market valuation will ...

Dr Abdul Ghafur highlights how media narratives, public perception, and investor behaviour intersected during the HMPV scare, ...

Chanelle Pharma, Ireland’s leading manufacturer of generic pharmaceuticals for human and animal health, has announces the ...

Maple Syrup Urine Disease (MSUD): A disorder characterized by the inability to break down certain branched-chain amino acids (leucine, isoleucine, and valine), leading to their accumulation in the ...

With few clouds, vast empty deserts and a well-developed electricity grid, Egypt has all the elements for a huge expansion in ...

GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to ...

Shares of GSK PLC GSK slipped 1.37% to £13.31 Monday, on what proved to be an all-around rough trading session for the stock ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...